By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Medivation, Inc. 

525 Market Street
36th Floor
San Francisco  California  94105  U.S.A.
Phone: 415-543-3470 Fax: 415-543-3411


Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial.

For more information, please visit us at

Key Statistics

Ownership: Public

Web Site: Medivation, Inc.
Employees: 18
Symbol: MDVN



Company News
Biotech Predictions for Large Cap Firms Include Medivation, Inc. (MDVN), Gilead Sciences, Inc. (GILD) 12/18/2014 12:15:08 PM
Medivation, Inc. (MDVN) Announces Participation At Upcoming Investor Conference 12/18/2014 9:55:25 AM
Medivation, Inc. (MDVN) And Astellas Pharma Inc. (ALPMY) Phase 3 PREVAIL Trial Named Clinical Advance Of The Year By SCRIP 12/12/2014 11:04:46 AM
Analysts Not Sold On Medivation, Inc. (MDVN)’s Xtandi as Breast Cancer Drug 12/10/2014 2:33:00 PM
Joseph Lobacki To Become Medivation, Inc. (MDVN)'s Chief Commercial Officer 11/26/2014 8:12:26 AM
Medivation, Inc. (MDVN) CEO David Hung Named National EY Entrepreneur Of The Year 2014 Overall Award Winner 11/19/2014 5:22:47 PM
Dr. David Hung, Founder, President And CEO Of Medivation, Inc. (MDVN), Named EY Entrepreneur Of The Year™ 2014 National Overall Award Winner 11/17/2014 12:06:13 PM
Medivation, Inc. (MDVN) Reports Third Quarter Financial Results And Provides Corporate Update 11/7/2014 12:17:12 PM
Medivation, Inc. (MDVN) Announces Participation At Upcoming Investor Conference 11/6/2014 1:55:09 PM
Medivation, Inc. (MDVN) And Astellas Pharma US Announce Phase 3 Study Of Enzalutamide in Men With High-Risk, Hormone-Sensitive, Non-Metastatic Prostate Cancer That Has Recurred Following Definitive Local Therapy 10/31/2014 12:45:31 PM